| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $154.2M | +110.5% |
| SG&A Expense | $18.3M | +3.8% |
| Operating Income | -$172.5M | -89.8% |
| Pre-tax Income | -$165.7M | -105.5% |
| Income Tax | $0 | — |
| Net Income | -$165.7M | -105.5% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $85.4M | +157.1% |
| Current Assets | $142.0M | -27.3% |
| Total Assets | $145.8M | -27.2% |
| Current Liabilities | $64.8M | +166.0% |
| Total Liabilities | $67.8M | +138.5% |
| Stockholders' Equity | $78.1M | -54.6% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$113.2M | -60.0% |
| Capital Expenditures | $91K | -82.3% |
| Investing Cash Flow | $100.3M | +217.5% |
| Financing Cash Flow | $65.1M | -59.8% |
| Free Cash Flow | -$113.3M | -59.0% |